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Abstract—Kynurenic acid (KYNA) is produced enzymatically in humans and animals from kynurenine.
Reports concerning changes of kynurenine metabolism during inﬂammation are available in the litera-
ture. Pyometra is a pathological condition characterized by the accumulation of pus in the uterine lumen
and bacterial infection. The objective of the study was to compare the serum and endometrial KYNA
concentrations in healthy bitches and those with pyometra. KYNAwas determined by means of high-
performance liquid chromatography with ﬂuorometric detection. The serum content of KYNA in bitches
with pyometra was signiﬁcantly higher than in healthy bitches. The KYNA content in the endometrium
of bitches with pyometra was higher, yet the difference was not statistically signiﬁcant. Our result
indicates that determination of KYNA might be a marker of pyometra in bitches.
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INTRODUCTION
Kynurenic acid (KYNA) was ﬁrst detected in dog’s
urine and described in 1853 by Liebig. It is produced in
vertebrates along the kynurenine pathway of tryptophan
metabolism [1]. KYNA is a ﬁnal product of the
kynurenine transamination [2]. Apart from its action on
neuronal glutamatergic receptors [3, 4], KYNA is also a
ligand of G protein-coupled receptor 35, which demon-
strates a high expression on the immune system and the
gastrointestinal tract components [5] as well as a ligand
of aromatic hydrocarbon receptor participating in the
process of carcinogenesis and mechanisms of immune
response modulation [6]. There are premises of KYNA’s
signiﬁcance in various inﬂammatory diseases [7–17].
Pyometra is one of the most frequently occurring
pathological conditions of the reproductive tract in adult
and older bitches, in the metestrus phase of the estrous
cycle. The disease is characterized by the accumulation
of a large amount of pus in the uterine lumen, which, in
consequence, leads to absorption of suppurating toxins
by blood and systemic disturbances, e.g., kidney and
liver damage [18].
Pyometra often constitutes a threat to the bitches’ life,
and, for this reason, it should be diagnosed and treated as
soon as possible. The primary treatment in a case of
pyometra is surgical intervention consisting of the simul-
taneous removal of both the uterus and ovaries [19].
So far, there are no literature data concerning the
determination of KYNA in inﬂammation of uterus in
animals. The objective of the study was to compare the
serum and endometrial KYNA concentrations in healthy
bitches and those with pyometra.
MATERIALS AND METHODS
All experimental protocols and procedures were
approved by the First Local Ethics Committee in Lublin.
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The study involved 20 bitches of various breeds and
mongrels treated in the Department and Clinic of Animal
Reproduction, Veterinary Faculty, University of Life
Sciences in Lublin. The animals were divided into two
groups. Control group consisted of ten clinically healthy
bitches, aged 2–6 years, between the 4–11th weeks after
estrous cycle, which underwent ovariohysterectomy on
the owners’ request. Study group included ten bitches,
aged 5–13 years, diagnosed with pyometra based on the
medical history, clinical examination, cytology tests,
vaginoscopy, and ultrasound examination as well as
hematological and blood biochemistry tests. Bitches in
this group were between 4 and 10 weeks after estrous
cycle. These animals underwent ovariohysterectomy
because of pyometra.
In both groups, the surgical procedures were carried
out under general anesthesia using intramuscular ket-
amine of 5–15 mg/kg b.w. (Narkamon 5 %®, Spofa,
Czech Republic), following premedication with subcu-
taneous atropine of 0.05 mg/kg b.w. (Atropinum
sulfuricum®, Polfa, Poland), and intramuscular xylazine
of 2 mg/kg b.w. (Rometar 2 %®, Spofa, Czech
Republic).
Prior to surgery, the blood was sampled (9 ml) from
the saphenous vein of all bitches to sterile centrifugation
tubes and silicone vacuette (Greiner Labortechnik
GmbH, Austria). After blood centrifugation, the serum
was frozen and kept at −80 °C until used.
Immediately after surgery, the uterine endometrium
biopsies were taken. The endometrium section, 1.0×1.0 cm,
was excised from the central right horn of the uterus, placed
in the plastic Eppendorf tubes and frozen at −80 °C.
KYNAwas investigated according to the method of
Turski et al. [20] and Shibata [21]. In brief, serum
samples were acidiﬁed with 1 N HCl and 50 %
trichloroacetic acid and then centrifuged. Tissue samples
were sonicated (1:5 wt/vol) in distilled water. The
resulting homogenate was centrifuged. The supernatant
was acidiﬁed with 1 N HCl and 50 % trichloroacetic
acid and then centrifuged. Supernatant was applied on
cation-exchange resin (Dowex 50 W+, Sigma). Eluted
KYNA was subjected to the HPLC (Varian HPLC
system, ESA catecholamine HR-80, 3 μm, C18 reverse-
phase column) and quantiﬁed ﬂuorometrically (excita-
tion, 344 nm; emission, 398 nm).
The results are presented as a mean ± standard
deviation or median values according to data distribution
and result of normality test. Data were analyzed using
Student t test or Mann–Whitney test. The signiﬁcance of
differences was determined at p<0.05.
RESULTS
All bitches with pyometra showed reduced appetite,
polydipsia, apathy, and enlarged abdominal integuments;
80 % of them developed purulent discharge from
reproductive organs. In all bitches, abdominal ultrasound
examinations revealed enlarged uterus of a diameter
ranging from 2 to 7 cm with a hypoechogenic content.
The mean amount of leucocytes in bitches with
pyometra was 27.5±8.0×109/l and was statistically
signiﬁcantly higher (p<0.05) compared to the values in
healthy bitches (11.4±2.5×109/l). The percentage of rod
neutrophils noted in bitches suffering from pyometra (5.9±
1.5 %) was statistically signiﬁcantly higher (p<0.05)
compared to that of healthy bitches (1.7±0.7 %).
According to the bacteriological tests of the uterine
purulent secretions, Escherichia coli was identiﬁed in
90 % of cases; in the remaining 10 %, Staphylococcus
spp. were detected.
The median serum content of KYNA in bitches
with pyometra and healthy bitches was 179.6 and 49.0
pmol/ml, respectively (Fig. 1). The difference was
statistically signiﬁcant (p<0.05). The median content of
KYNA in the endometrium of bitches with pyometra
and in healthy animals was 334.1 and 121.5 pmol/g,
respectively (Fig. 2). The difference did not reach
statistical signiﬁcance (p>0.05).
Average age of animals with pyometra was 10.8±
2.2 years and was signiﬁcantly higher (p<0.05) com-
pared to that of healthy bitches (3.4±1.4 years). There
was no correlation between KYNA content and age in
healthy bitches (data not shown).
DISCUSSION
Results of clinical examination, laboratory, and
bacteriological tests conﬁrm the diagnosis of pyometra
in the investigated bitches. In bitches with pyometra, a
signiﬁcant increase of blood KYNA concentration has
been demonstrated. Our result is consistent with other
reports. An increase of KYNA in serum was reported in
generalized sepsis in humans [7] and in patients with
chronic kidney disease [8]. A signiﬁcant increase of
KYNA in patients with meningitis, septicemia and
various autoimmunological diseases as well as with
bacterial, viral, fungal, and parasitic infections was
demonstrated in the cerebrospinal ﬂuid and in the brain
[9]. Similarly, an increase in KYNA concentration in the
brain of mice infected with the ﬂu virus has been observed
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[15]. The increase in KYNA concentration in the spinal
cord has been demonstrated in the model of allergic
encephalitis and myelitis in rats [16]. Elevated KYNA
concentration in the saliva of the patients with odonto-
genic abscesses has also been found [17]. In our study, a
tendency toward an increase of KYNA concentration was
found in the endometrium of bitches with pyometra;
however, the difference did not reach statistical signiﬁ-
cance probably due to high variability between the results
and limited number of investigated subjects.
It is known that frequency of pyometra increases
with the age of animals [22]. In our study, the animals
diagnosed with pyometra were signiﬁcantly older than
the control ones. It has been described that in 18-month
old rats, the KYNA blood concentration is higher than in
3-month old rats [23]. In contrast, no correlation
between the KYNA blood concentration and age in
humans has been observed [24]. We found no correla-
tion between the age and KYNA blood concentration in
bitches.
KYNA is produced from kynurenine, and the rate
of its synthesis depends mainly on precursor availability.
Kynurenine is converted from tryptophan by indole-
amine 2,3-diooxygenase, which activity is stimulated in
the course of inﬂammatory processes [25, 26]. More-
over, it was found that lipopolysaccharide enhances
KYNA production in human gingival ﬁbroblasts [17].
Thus, it can be assumed that an increase in KYNA
content is a result of inﬂammatory response.
Interestingly, data from animal studies indicate that
an administration of exogenous KYNA results in anti-
inﬂammatory action. Glavin et al. demonstrated that
KYNA attenuates experimental gastric ulcer formation
produced by ethanol, stress, or toxins derived from the
Atlantic coast mussels [27–29]. Kaszaki et al. found out
that KYNA alleviates the inﬂammation resulting from
experimental colon obstruction in dogs [30]. KYNA
restored the tone of the colon and decreased motility
index of the giant colonic contractions. It has been
demonstrated that KYNA treatment signiﬁcantly sup-
pressed the increase in plasma nitrite/nitrate (NOx) and
reduced elevated activity of xanthine oxidase and
xanthine dehydrogenase [30]. Similarly, KYNA de-
creased the motility and increased the tone of the colon
in the acute ulcerative colitis model. Moreover, it reduced
elevated activity of xanthine oxidoreductase, nitric oxide
synthase, and myeloperoxidase [31]. In septicemia
induced by the administration of lipopolysaccharide in
mice, KYNA signiﬁcantly reduced the mortality rate of
the animals and inhibited nitric oxide, as well as increased
tumor necrosis factor α concentration [32].
Based on our results, a suggestion that KYNA
concentration measurement might be an inﬂammation
Fig. 1. Scatter plots of kynurenic acid (KYNA) concentration in plasma
of bitches. Samples were collected from bitches that underwent ovar-
iohysterectomy. Results are expressed as picomoles of KYNA/milliliter.
The horizontal bar represents the median value.
Fig. 2. Scatter plots of kynurenic acid (KYNA) concentration in endo-
metrium of bitches. Samples were collected from bitches that underwent
ovariohysterectomy. Results are expressed as picomoles of KYNA/gram
wet weight. The horizontal bar represents the median value.
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indicator of pyometra in bitches seems justiﬁed. It is also
possible to call for application of KYNA in the treatment
of pyometra, which requires conﬁrmation in further
experimental studies.
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